Tata Elxsi Launches Global Offshore Development Center for Terumo Corporation
Pune, India – March 19, 2026 – Tata Elxsi, a global leader in design and technology services, and Terumo Corporation, a global medical innovation company, have inaugurated a new 'Terumo-Tata Elxsi Offshore Development Center'. The center will focus on developing Terumo’s cardiac and vascular solutions, enhancing engineering and innovation capabilities and providing lifecycle support across international markets.The collaboration leverages Tata Elxsi's expertise in design, engineering, verification, regulatory compliance, and localization, combined with the use of AI, GenAI, and digital capabilities in software engineering. This aims to accelerate development, regional adaptation, and address demand for patient-centric medical devices while improving cost efficiency and product differentiation.
Fumihisa Hirose, Company President, Cardiac & Vascular Company Terumo Corporation, stated that the new center strengthens Terumo’s ability to innovate and deliver high-quality medical technologies globally. He noted that Tata Elxsi’s expertise will accelerate the global product roadmap while maintaining safety and compliance standards.
Sreevatsa Sahasranaman, Sr. Vice President & Head - Healthcare & Life Sciences, Tata Elxsi, described the center as a long-term partnership to drive innovation and cost efficiencies across Terumo’s Cardiovascular portfolio. He added that Tata Elxsi is committed to combining design, engineering, and regulatory capabilities with AI- and GenAI-powered technologies to support the introduction of next-generation medical technologies to global and emerging markets.
About Tata Elxsi
Tata Elxsi is a global design and technology services company headquartered in Bangalore. It serves healthcare, automotive, broadcast, and communications industries through design studios, development centers, and innovation hubs worldwide. The Healthcare & Life Sciences practice is ISO 13485 certified and collaborates with global medical device and pharmaceutical companies on next-generation product development.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.